Blueprint Investment Partners’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-781
Closed -$406K 194
2024
Q4
$406K Sell
781
-565
-42% -$311K 0.06% 141
2024
Q3
$833K Buy
1,346
+181
+16% +$107K 0.15% 74
2024
Q2
$644K Sell
1,165
-51
-4% -$29.2K 0.14% 68
2024
Q1
$707K Buy
1,216
+784
+181% +$440K 0.14% 65
2023
Q4
$229K Buy
+432
New +$209K 0.06% 124
2023
Q2
Sell
-1,260
Closed -$726K 233
2023
Q1
$726K Buy
1,260
+30
+2% +$16.9K 0.17% 81
2022
Q4
$677K Buy
1,230
+82
+7% +$43.5K 0.14% 106
2022
Q3
$582K Buy
1,148
+308
+37% +$172K 0.16% 74
2022
Q2
$456K Sell
840
-4,816
-85% -$2.65M 0.12% 86
2022
Q1
$3.34M Buy
5,656
+1,078
+24% +$619K 0.86% 29
2021
Q4
$3.05M Buy
4,578
+1,772
+63% +$1.11M 0.75% 37
2021
Q3
$1.6M Buy
2,806
+1,105
+65% +$606K 0.8% 27
2021
Q2
$858K Buy
1,701
+232
+16% +$109K 0.69% 26
2021
Q1
$670K Buy
1,469
+1,468
+146,800% +$701K 0.52% 28
2020
Q4
$309 Sell
1
-663
-100% -$311K 0.25% 38
2020
Q3
$309K Buy
+664
New +$274K 0.24% 42

Other funds holding TMO

Blueprint Investment Partners's TMO Position: Q1 2025 in Review

Blueprint Investment Partners sold out of Thermo Fisher Scientific (TMO) in Q1 2025, closing a stake of 781 shares — an estimated $406K sold.

Blueprint Investment Partners first reported a position in TMO in Q3 2020 and held it in 16 quarters. The position peaked at $3.34M in Q1 2022. 2,570 funds tracked by Wall St. Rank hold TMO as of Q1 2025.

  • Blueprint Investment Partners reported no remaining Thermo Fisher Scientific position as of Q1 2025 after selling out during the quarter.
  • Blueprint Investment Partners sold 781 Thermo Fisher Scientific shares in Q1 2025, an estimated $406K.
  • Blueprint Investment Partners first reported a position in Thermo Fisher Scientific in Q3 2020 and held it in 16 quarters.
  • Blueprint Investment Partners's Thermo Fisher Scientific position peaked at $3.34M in Q1 2022.
  • 2,570 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.

Based on Blueprint Investment Partners's 13F filing for Q1 2025, filed 12 May 2025.